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Summary
Background: Several drugs can cause prolonged QT interval, as well as prolonged QT dispersion (QTd) in 
electrocardiographic (EKG) recordings. QTd may be a potentially sensitive marker of increased risk of cardiac arrhythmias 
and sudden cardiac death. Metformin is an effective antihyperglycemic agent used in the treatment of diabetes. However, 
studies have correlated dose-dependent effects of metformin on glycemia and cardiovascular risk markers.
Objective: To evaluate the dose-response effects of metformin on QT and QTd of diabetic rats.
Methods: Male Wistar rats were distributed in five groups: non-treated control (C), non-treated diabetics (D), diabetics 
treated with metmorfin at the doses of 3.5, 30 and 74 µg/kg/bw (DM 3.5, DM 30 and DM 74). Diabetes was induced 
by an alloxan injection (40 mg/kg, IV). EKG was recorded (days 1, 15 and 30) using four electrodes inserted into the 
subcutaneous layer of the paws. Both RR and QT intervals were measured, and then corrected QT and QT dispersion 
values were calculated.
Results: The DM 3.5 and DM 30 groups showed a significant reduction of glycemia (p< 0.05) when compared with the 
high dose (DM 74). Rats of the DM 74 group presented prolonged QTc, QTd and QTcd intervals, whereas rats of the DM 
3.5 and DM 30 groups presented less prolonged intervals.
Conclusion: Metformin at high doses provided greater dispersion of the QT interval probably because of the increased 
ventricular repolarization inhomogeneity, whereas at low doses decreased QT intervals were observed in diabetic rats. 
(Arq Bras Cardiol 2008; 90(4): 232-238)
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LQTS may be congenital – when abnormalities in sodium 
or potassium channels occur, or acquired – resulting from 
the use of medications, electrical abnormalities or metabolic 
disorders. The QT interval corresponds to the time necessary 
for the complete ventricular electrical excitation and recovery 
and is, therefore, the measurement of the duration of the 
“electrical” systole, which includes ventricular depolarization 
and repolarization, that is, the total duration of the ventricular 
electrical activity6. The QT interval varies inversely with heart 
rate (HR), so that the higher the HR, the shorter the QT and 
vice versa. Accordingly, it should be corrected for HR, thus 
generating the QTc, which is preferably used7. Other parameters 
to be assessed are QT dispersion and QTc dispersion (QTd 
and QTcd, respectively). This dispersion would result from 
inhomogeneity of repolarization times, and is defined as the 
difference between the maximum and minimum QT in the 
twelve electrocardiographic leads8. QT dispersion is a marker 
of arrhythmogenesis, and its analysis is a noninvasive method 
for the detection of ventricular repolarization heterogeneity9. 
Additionally, some studies associate increased QTd intervals 
with a higher risk of sudden death10,11 and as a prognostic 
index in heart failure and hypertrophic cardiomyopathy8,12. 
In diabetic individuals, increased QT interval is considered a 
precursor of increased risk of sudden death13.
Depending on their dosages, certain medications may 
prolong the duration of the ventricular action potential and 
Introduction
Diabetes is a metabolic disorder characterized by increased 
blood glucose resulting from alterations in protein, lipid and 
carbohydrate metabolism due to impaired secretion of or 
peripheral resistance to insulin. These alterations increase 
the tendency to the development of cardiovascular diseases 
and neuropathies, which represent one of the major causes 
of death of patients1,2. Alterations in carbohydrate and lipid 
metabolism as well as electrolytic changes in blood calcium 
and potassium may cause modifications in the cardiovascular 
structure and physiology which, in turn, lead to alterations in 
electrocardiographic recording3,4. 
Electrocardiogram (ECG) is one of the most important 
methods in the diagnosis of heart diseases5. Depending on 
the extent and areas damaged, the propagation of action 
potentials in the heart muscle changes ECG waves and their 
respective intervals. 
Among the main changes observed is the QT interval 
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the QT interval by means of different ionic mechanisms.
The biguanide metformin is an antihyperglicemic agent 
used to reduce blood glucose and consequently to improve 
the metabolic profile. It reduces blood glucose levels by 
inhibiting gluconeogenesis and in the presence of insulin it 
stimulates peripheral glucose uptake by the tissues – mainly 
skeletal muscles - and decreases absorption of glucose from the 
gastrointestinal tract. Its direct effect on b cells is still debatable. 
Metformin does not cause hypoglycemia, but rather reduces 
glycosylated hemoglobin levels and improves the lipid profile 
and fibrinolytic activity14,15.
Despite the beneficial effects of metformin, studies have 
demonstrated that its use at high doses does not decrease 
hyperglycemia and increases the cardiovascular risks16-20.
Gastrointestinal disorders such as diarrhea are common, and 
the intestinal absorption of group B vitamins, especially folate, 
is impaired during chronic therapy. Frequently, this deficiency 
increases plasma homocysteine levels, which accelerate the 
progression of vascular disease due to adverse effects on blood 
vessels, clotting factors, and endothelium. One study found an 
association between high homocysteine levels and the overall 
mortality in patients with atherogenic disease15.
In some circumstances, metformin may lead to lactic 
acidosis, especially in patients with clinical conditions that 
predisposed to this complication, such as heart failure or 
myocardial infarction15.
Additionally, preliminary results (unpublished) showed that 
high metformin doses such as those recommended for human 
patients promoted a great increase in cardiac glycogen in 
alloxanized rats, whereas at low doses this increase was milder. 
In diabetic patients, the increased glycogen concentration 
in the ventricles is apparently associated with the severity of 
diabetes, and makes the heart more susceptible to the effects of 
ischemia21,22, in addition to leading to cardiac malfunctioning, 
since its accumulation in the conductive tissue is the cause of 
sinus and atrioventricular node dysfunction23.
Based on these findings, we investigated the effects of low and 
high metformin doses on blood glucose and on the QT interval, 
as well as on QTc, QTd, and QTcd of alloxan diabetic rats.
Methods
Animals
Male albino Wistar rats aged 10 weeks were supplied 
by Unicamp’s vivarium to be used in this study. They were 
kept in the vivarium of the Department of Physiology and 
Biophysics for adaptation for two weeks. The rats were fed 
on feed (Purina rodent) and had ad libitum access to water 
in a photoperiodic cycle of 12 h light and 12 h dark, at 22 ± 
2o C. The experimental protocol was approved by the Ethics 
Committee on Animal Experimentation of Unicamp under 
number 262-1. 
Induction of diabetes
Before induction of diabetes, the rats were fasted for 24 
hours with free access to water. After being anesthetized with 
sodium pentobarbital (40 mg/kg of body weight), the rats 
were injected with alloxan in saline (40 mg/kg/bw, IV, pH 4.5, 
Sigma™)24,25. Established diabetes was verified by the presence 
of glucose in urine the next day. 
Treatment with metformin and groups
After induction of diabetes, the treatment was started. The 
rats in the groups treated received metformin (Lipha, Lyon, 
France) diluted in drinking water (3.5, 30 and 74 µg/g/bw) 
for 30 days, thus comprising the following groups: control 
(C; n = 5); diabetes (D; n = 6); diabetes metformin [3,5 
µg/g/bw] (DM3.5; n = 8); diabetes metformin [30 µg/g/bw] 
(DM30; n = 7); and diabetes metformin [74 µg/g/bw] 
(DM74; n = 8). 
Electrocardiogram
Anesthetized rats (sodium pentobarbital, 40 mg/kg/bw) 
were kept in the supine position with spontaneous breathing 
for ECG recording. The electrodes were connected to the 
computer channels (Heart Ware System), and six standard 
waves were recorded (I, II, III, aVR, aVR and aVF) with a 2N 
sensitivity at a 50-mm/second speed. The QT interval was 
measured in three consecutive beats from the beginning of 
the QRS-complex to the point of return of the T wave to 
the isoelectric line, defined as the TP segment26. QTd was 
calculated in absolute values, by subtracting the shortest QT 
interval from the longest (QT = QT max – Qt min). This value 
was converted into a percentage (%QTd) by correcting the 
QTd for the shortest QT interval and multiplying this value 
by 100 (%QTd = Qt max – QT min/QT min x 100). The 
QT interval was corrected for the heart rate using Bazett’s 
formula (QTc = QT/√R-R) and the QTc interval dispersion 
was further calculated by subtracting the minimum QTc 
interval from the maximum QTc interval (QTcd = QTcmax 
- QTcmin). The percentage QTcd was also calculated 
(%QTcd = Qtcmax - QTcmin/ Qtcmin x 100). The analyses 
were made by a single observer blinded to the treatment 
the animals received, so as to minimize divergences in the 
dispersion measurement. 
Determination of plasma glucose, Na+, K+ and Ca2+
Plasma glucose was determined with the glucose oxidase 
method, using a commercial kit (Laborlab, Sao Paulo, Brazil). 
Na+ and K+ were determined using the selective ion electrode 
method (Roche™). Total serum calcium was measured using 
the colorimetric method with cresolftaleine (o-cresolftaleine 
complexone – Roche™)27, with an automated analyzer 
(Hitachi™).
Statistics
The results were expressed as mean ± MSD. Data were 
evaluated using the analysis of variance for two factors, 
followed by Tukey’s test. Significant values were considered 
those whose differences were lower than 5%. 
Results
Effects of metformin on blood glucose
Blood glucose levels did not differ among the rats of all 
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At the end of the experiment, similar levels were observed in 
rats of the control group. 
Administration of alloxan induced severe hyperglycemia 
on day 15, which was maintained until day 30 in the rats of 
group D (563 ± 61 mg/dl, p < 0.001; compared with blood 
glucose prior to alloxan administration). Rats that received 
daily metformin doses of 3.5 (DME.5) and 30 (DM30) mg/kg 
showed lower blood glucose levels on days 15 and 30 (381 ± 
37 and 360 ± 14, respectively) of treatment when compared 
with rats of the control diabetic group. The administration 
of metfomin at 74 mg/kg marginally reduced blood glucose 
after day 30 in comparison with control diabetic rats (p 
>0.05) (Fig.1).
Effects of metformin on ECG
Figure 2 (A, B, C and D) shows that the QT (2A) and 
QTc (B) intervals, as well as QTd (2C) and QTcd (2D), were 
similar at the beginning of the experimental period. In 
diabetic rats, these intervals increased after 15 days of the 
administration of alloxan and remained similar 30 days later. 
On days 15 and 30, the QT interval of diabetic rats treated 
with 3.5 and 30 mg/kg was similar to that observed in the 
non-diabetic control group, but was significantly longer in 
rats treated with metmorfin at 74 mg/kg. The QTc interval of 
rats treated with lower metmorfin doses (3.5 and 30 mg/kg) 
was longer than that observed in rats of the control group 
(non-diabetic) 15 and 30 days after the administration of 
alloxan. However, it was significantly shorter than the values 
observed in diabetics (non-treated) and diabetics treated 
with metformin at high doses (74 mg/kg). Only metformin 
at lower doses (3.5 and 30 mg/kg) decreased QT and QTc 
dispersion when compared with the group of non-treated 
diabetics. However, these differences were more evident 
after 30 days of treatment. 
Figure 1 - Changes in glycemia (mg/dl) of rats after alloxan induction and after 15 and 30 days of treatment with metformin at low (3.5 µg/g/bw), medium (30 µg/g/bw) 
and high doses (74 µg/g/bw). Data are expressed as mean ± MSD. a - significantly different from the control group on day 15 of the experimental period (p<0.05); b 
- significantly different from the control group on day 30 of the experimental period (p<0.05); c - significantly different from the diabetes group (not treated) on day 1 of the 
experimental period (p<0.05); d - significantly different from the diabetes metformin 3.5 group on day 1 of the experimental period (p<0.05); e - significantly different from 
the diabetes metformin 30 group on day 1 of the experimental period (p<0.05); f - significantly different from the diabetes metformin 74 group on day 1 of the experimental 
period (p<0.05); g - significantly different from the diabetes group (not treated) on day 15 of the experimental period (p<0.05); h - significantly different from the diabetes 
group (not treated) on day 30 of the experimental period (p<0.05).
Effects of metmorfin treatment on serum ion 
concentration
Table 1 shows a decrease in serum K+ concentration of 
diabetic rats (non-treated) in comparison with the control 
group (non-diabetic). 
It also shows an increase in Ca2+ concentration only in the 
group treated with metformin at high doses. No alterations 
were observed in the other parameters. 
Discussion
Type-2 diabetes is characterized by alterations in glucose 
and lipid metabolism, partly due to resistance to insulin 
action in peripheral tissues. If untreated, it may lead to several 
complications such as increased cardiovascular risk1,2. 
The biguanide metformin is an antihyperglycemic agent 
used in the treatment of type-2 diabetics. However, the action 
mechanism of metformin is still unclear. 
Studies have shown that metformin activates AMP activated 
protein kinase (AMPK) in liver cells and skeletal muscle of 
rats28. Recent studies indicate that AMPK plays a role in 
the regulation of glucose and lipid metabolism. AMPK is an 
enzyme that promotes energy availability and is activated by 
skeletal muscle contraction and during myocardial ischemia; 
it is involved in the stimulation of glucose transport and fatty 
acid oxidation. 
In the liver, AMPK activation results in increased fatty 
acid oxidation and decreased production of glucose, 
cholesterol and triglyceride29. This effect contributes to 
a reduction in blood glucose and improvement of the 
metabolic profile, and leads to increased glycogen in the 
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Figure 2 A, B, C, D - Changes in QT, QTc, QTd, QTcd intervals (ms) in rats after alloxan induction and after 15 and 30 days of treatment with metformin at low (3.5 
µg/g/bw), medium (30 µg/g/bw) and high doses (74 µg/g/bw). Data are expressed as mean ± MSD. a - significantly different from the control group on day 15 of the 
experimental period (p<0.05); b - significantly different from the control group on day 30 of the experimental period (p<0.05); c - significantly different from the diabetes 
group (not treated) on day 1 of the experimental period (p<0.05); d - significantly different from the diabetes group (not treated) on day 1 of the experimental period 
(p<0.05); e - significantly different from the diabetes group (not treated) on day 30 of the experimental period (p<0.05); f - significantly different from the diabetes metformin 
3.5 group on day 1 of the experimental period (p<0.05); g - significantly different from the diabetes metformin 30 group on day 1 of the experimental period (p<0.05); h 
- significantly different from the diabetes metformin 74 group on day 30 of the experimental period (p<0.05); i - significantly different from the diabetes metformin 74 group 





However, other studies demonstrated that high-dose 
metformin did not reduce hyperglycemia in diabetic animals, 
but could increase the cardiovascular risks16-20.
Our results (Figure 1) show that metformin at a high 
dose equivalent to that recommended for diabetic patients 
(74µg/g/bw) did not reduce blood glucose in diabetic rats, 
whereas at low (3.5 µg/g/bw) and medium doses (30 µg/g/
bw), it significantly reduced blood glucose in comparison 
with untreated diabetic rats. However, the blood glucose 
reduction induced by low doses of metformin was not enough 
to normalize blood glucose levels. 
The inefficacy of high doses of metformin in reducing 
blood glucose may have been caused by decreased b-cell 
responsiveness to glucose. An in vitro study with b cells showed 
that metformin at high doses (1 mM) and prolonged exposure 
(24 hours) activated AMPK and thus partially inhibited the 
synthesis and release of insulin in b cells, which caused the 
reduction of their glucose responsiveness32.
Additionally, metformin at therapeutic doses was observed 
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Table 1 - Effects of the treatment with metformin at low doses (3.5 
µg/g/bw), at medium doses (30 µg/g/bw) and at high doses (74 
µg/g/bw) on serum potassium (mEq/l), sodium (mEq/l) and calcium 
(mg/dl) concentrations. Data are expressed as mean ± MSD
Groups Sodium Potassium Calcium
Control 140 ± 1.08 4.80 ± 0.06 7.05 ± 0.33
Diabetes 127 ± 2.4 4.00 ± 0.11 a 6.80 ± 0.18
DM 3.5 136 ± 2.8 4.73 ± 0.03 7.10 ± 0.30
DM 30 137 ± 1 4.92 ± 0.08 6.64 ± 0.52
DM 74 134 ± 1.4 4.80 ± 0.10 8.76 ± 0.30 a, b,c,d
a - significantly different from the control group (n = 4) on day 30 of the 
experimental period (p< 0.05); b - significantly different from the diabetes 
group (non-treated) (n = 4) on day 30 of the experimental period (p< 0.05); c 
- significantly different from the diabetes metformin 3.5 group (n = 5) on day 30 
of the experimental period (p< 0.05); d - significantly different from the diabetes 
metformin 30 group (n = 5) on day 30 of the experimental period (p< 0.05).
portion of the b subunity of its receptor. However, high 
doses of metformin inhibited tyrosine kinase activity and, 
consequently, insulin action33.
Diabetes, per se, causes changes in MAP kinase and in 
glucose transporters. The enhancement of K+ currents in 
ventricular cells depends on the activation of MAP kinase, 
which reflects the synthesis of new channels. The decrease 
of insulin in diabetics probably leads to a reduction in K+ 
currents in the epicardium, thus causing increased duration 
of the cardiac action potential34.
The alterations promoted in carbohydrate and lipid 
metabolism and in electrolyte concentrations may cause 
changes in the cardiovascular physiology and structure, which 
can be recorded in the electrocardiogram. One of the most 
common problems detected in diabetics is prolongation of the 
QT interval, as well as of QTc, QTd and QTcd. This is due to a 
late depolarization and/or repolarization of the cardiac action 
potential, thus leading to an increased risk of arrhythmias and 
sudden death35.
Although the QT interval is used as a noninvasive method 
to identify the risk of developing malignant ventricular 
arrhythmias and sudden death, flaws are actually expected in 
the system proposed. When the equation QT max – QT min is 
used, a 12-lead ECG with a well-defined T-wave in each lead 
should ideally be obtained36. This was a limitation in our study 
because only six leads can be recorded in rats according to the 
methodology used by other authors37. Additionally, in several 
situations it was impossible to detect the end of the T-wave. In 
this circumstance, the methodology indicates that excluding 
this interval from the analysis is the most proper thing to do36, 
as we did in our results. However, despite these limitations, 
some measures were taken to minimize the discrepancies 
in the dispersion measurement. The same electrode was 
used in all electrocardiographic recordings;   the site where 
it was placed was also standardized. The ECG was always 
performed in the morning so as to lessen the possible effects 
of the circadian rhythm. Additionally, one single observer 
analyzed the QT interval in three consecutive beats, in order to 
decrease counting errors26. After determination of the values, 
no statistically significant difference was found between the 
results calculated. 
Thus, despite the limitations of the study, the QTc, QTd and 
QTcd intervals increased in alloxan diabetic rats, as shown in 
Figure 2 (B, C and D).
The causes of the increased intervals are unknown. 
However, this alteration observed in the electrocardiogram 
may be explained in function of polyuria, which is the most 
common clinical manifestation of diabetes mellitus38. Polyuria 
observed in diabetic patients is traditionally attributed to 
the osmotic diuresis secondary to increased blood glucose 
(glicosuria)37. The excessive urinary loss causes a reduction 
of potassium39 which can be responsible for the increased 
membrane repolarization period40, with a consequent increase 
in the QT interval. The reduction in serum K concentration 
observed in rats of the diabetes group is shown in Table 1. 
The increased QT interval dispersion may also result from 
alterations in voltage-gated K+ channels41. In fact, diabetes 
may change the magnitude of K+ channels involved in the 
cardiomyocyte membrane repolarization process34, thus 
affecting the cardiac tissue. 
Treatment of diabetic rats with high doses of metformin (74 
µg/g) caused an increase in QT, QTd, QTc, and QTcd on days 
15 and 30 of the experimental period (Figure 2 A-D).
This increase may result from the hypercalcemia 
observed in this group (Table 1), since increased calcium 
concentrations reduce the ventricular conduction velocity 
and shorten the effective refractory period, and thus may 
cause arrhythmias42.
However, factors that were not evaluated in this study may 
also have contributed to the increased QT interval. Persistent 
AMPK activity, as occurs during treatment with metformin at 
high doses, may promote mutations in PRKAG2, the gene 
for γ2 regulatory subunity of AMP-activated protein kinase. 
This mutation may increase glucose uptake by stimulating 
translocation of the glucose transporter GLUT-4 to the plasma 
membrane and increase hexokinase activity, thus leading to 
glycogen accumulation, which may cause sinus node and 
atrioventricular node dysfunction22,24.
Additionally, AMPK activation also promotes a dose-
dependent increase in glycolysis and fatty acid oxidation 
in cardiomyocytes. Increased fatty acid oxidation inhibits 
glucose oxidation, and the acetyl-coA produced may inhibit 
the pyruvate-dehydrogenase complex, thus limiting pyruvate 
oxidation. These events lead to increased glycolysis and, in this 
situation, the protons and lactate produced accumulate and 
provoke a decrease in pH, intracellular calcium overload and 
subsequent cell death, thus reducing the cardiac functional 
capacity16. 
However, metformin at low and medium doses decreased 
the QT, QTc, QTd, and QTcd intervals, thus suggesting 
improved ventricular electric conduction. Additionally, serum 
electrolytes (calcium, potassium and sodium), which are other 
factors that may affect the electric conductivity, did not change 
in these groups.  
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